REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Merdury Biopharmaceutical Corporation (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Merdury Biopharmaceutical Corporation Profile Updated: July 09, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Mercury Biopharmaceutical Corporation is engaged in in rapid-acting and specialty drug development. The company’s main products rapid-acting and specialty drugs. The company was established in 2019 and is headquartered in New Taipei City, Taiwan.

Headquarters
15F.,No. 653-1, Bannan Rd., Zhonghe Dist
New Taipei City; New Taipei City;

Contact Details: Purchase the Merdury Biopharmaceutical Corporation report to view the information.

Website: http://merdury.com

Basic Information
Total Employees:
Purchase the Merdury Biopharmaceutical Corporation report to view the information.
Outstanding Shares:
Purchase the Merdury Biopharmaceutical Corporation report to view the information.
Financial Auditors:
Purchase the Merdury Biopharmaceutical Corporation report to view the information.
Incorporation Date:
July 16, 2019
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
General Manager
Ownership Details
Purchase this report to view the information.
6.41%
Purchase this report to view the information.
5.58%
Purchase this report to view the information.
5.29%
Purchase this report to view the information.
0.13%
Purchase this report to view the information.
Subsidiaries
Merdury Biopharmaceutical Inc. (United States)
100%
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
No results were found for this company.

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo